| Analysis | Metabolite Name | Measured Value | Units | Group | TIMEPOINT |
|---|---|---|---|---|---|
| Reversed phase NEGATIVE ION MODE | glycerol | 0.2807 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.2924 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.3038 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.3525 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.4157 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.4262 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.4323 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.4361 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.4609 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.4633 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.4694 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.4718 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.4806 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.4877 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.5240 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.5342 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.5534 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.5536 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.5696 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.5732 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.5899 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.6003 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.6059 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.6190 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.6265 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.6445 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.6457 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.6511 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.6549 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.6702 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.6710 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.6754 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.6771 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.6811 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.6832 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.6858 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.6896 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.6906 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.6947 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.6969 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.6970 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.7164 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.7191 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.7289 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.7474 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.7484 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.7629 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.7652 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.7653 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.7658 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.7705 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.7777 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.7828 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.8124 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.8148 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.8163 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.8217 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.8248 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.8249 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.8281 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.8315 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.8335 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.8376 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.8693 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.8703 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.8708 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.8721 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.8734 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.8761 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.8812 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.8869 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.8942 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.8945 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.8956 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.8974 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.9050 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.9110 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.9113 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.9173 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.9303 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.9313 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.9327 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.9395 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.9410 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.9442 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.9547 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.9564 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.9567 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.9734 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.9739 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.9764 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.9891 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 0.9957 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.0000 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.0043 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.0053 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.0065 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.0079 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.0098 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.0225 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.0319 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.0375 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.0381 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.0493 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.0694 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.0700 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.0727 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.0745 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.0758 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.1083 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.1086 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.1172 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.1310 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.1368 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.1403 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.1561 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.1589 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.1953 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.2057 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.2165 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.2405 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.2552 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.2620 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.2749 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.2915 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.3009 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.3026 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.3196 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.3218 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.3480 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.3533 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.3571 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.3623 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.3715 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.3798 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.3816 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.3836 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.3916 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.4083 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.4124 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.4147 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.4228 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.4518 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.4570 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.4608 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.4675 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.4737 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.5150 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.5362 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.5396 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.5467 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.5858 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.6101 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.6160 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.6203 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.6467 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.6470 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.6735 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.7014 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.7294 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.7580 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.7654 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.7772 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.7982 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.8734 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.8829 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.8837 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.8846 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.9011 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.9181 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.9569 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.9575 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycerol | 1.9771 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 2.0237 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycerol | 2.0765 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycerol | 2.1169 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | glycerol | 2.1533 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycerol | 2.3105 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycerol | 2.5203 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 2.5335 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycerol | 2.6122 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 2.9655 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycerol | 3.0043 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | glycerol | 3.2006 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycerol | 3.3062 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycerol | 3.3297 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | glycerol | 3.8228 | scaled units | Low-Dose | -0.5HR |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|